Leerink Partnrs Estimates Sanofi’s Q4 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Investment analysts at Leerink Partnrs reduced their Q4 2024 earnings estimates for Sanofi in a research report issued to clients and investors on Sunday, October 27th. Leerink Partnrs analyst D. Risinger now expects that the company will earn $0.83 per share for the quarter, down from their prior estimate of $0.94. The consensus estimate for Sanofi’s current full-year earnings is $4.25 per share. Leerink Partnrs also issued estimates for Sanofi’s FY2025 earnings at $4.67 EPS.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 20.59%. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.55 EPS.

Several other research analysts have also recently commented on the stock. Argus raised their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Down 1.0 %

Shares of SNY stock opened at $53.83 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The stock has a market cap of $136.61 billion, a PE ratio of 27.46, a price-to-earnings-growth ratio of 1.55 and a beta of 0.60. The business’s fifty day moving average is $56.06 and its 200-day moving average is $51.89. Sanofi has a 1 year low of $44.05 and a 1 year high of $58.97.

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently bought and sold shares of SNY. POM Investment Strategies LLC acquired a new position in shares of Sanofi during the 2nd quarter worth about $25,000. Larson Financial Group LLC increased its position in Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after buying an additional 500 shares during the period. Northwest Investment Counselors LLC acquired a new position in shares of Sanofi during the third quarter worth approximately $29,000. Palisade Asset Management LLC bought a new stake in shares of Sanofi in the first quarter valued at approximately $31,000. Finally, Concord Wealth Partners grew its stake in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.